Advertisement
A vs DHR
Which Stock Would AI Choose? Agilent Technologies (A) vs. Danaher Corporation (DHR) Stock Comparison
Key Takeaways
- Both A and DHR operate in the life sciences and diagnostics space, with overlapping exposure to healthcare end markets.
- DHR reported first-quarter 2026 revenue growth of 3.5% year-over-year and raised full-year guidance, while preparing to release second-quarter results on July 21, 2026.
- A maintains a focused portfolio in analytical instruments and laboratory solutions, with performance closely tied to biopharma and academic research spending trends.
- Recent market activity shows DHR benefiting from acquisition integration and earnings momentum, whereas A reflects broader sector stability amid fluctuating demand.
- Sector sentiment remains cautious for both due to macroeconomic pressures on capital equipment purchases, though diagnostics and consumables segments provide relative resilience.
- Relative positioning favors companies with diversified platforms and recurring revenue streams in the current environment.
Introduction
This comparison examines A (Agilent Technologies) and DHR (Danaher Corporation), two established players in the life sciences tools and diagnostics sector. Investors and traders focused on healthcare exposure, earnings consistency, and M&A (mergers and acquisitions) activity may find the analysis relevant. The review centers on observable factors such as recent revenue trends, upcoming catalysts, and sector positioning to highlight contrasts in business models and market responses without forward-looking speculation.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies provides analytical instruments, reagents, software, and services primarily for pharmaceutical, biotechnology, academic, and environmental laboratories. The company’s revenue derives from a mix of instruments and higher-margin consumables and services. In recent weeks, stock performance has aligned with broader life sciences sector movements, influenced by capital spending patterns among biopharma clients and research institutions. Sentiment has remained measured amid ongoing integration of prior acquisitions and steady demand for core laboratory solutions, with emphasis on recurring revenue components helping to moderate volatility.
Danaher Corporation (DHR) Overview and Recent Performance
Danaher Corporation operates a diversified portfolio spanning life sciences, diagnostics, and environmental solutions through multiple operating companies. Recent market activity reflects positive response to first-quarter 2026 results showing 3.5% revenue growth and 9.5% adjusted EPS (earnings per share) growth, along with an upward revision to full-year guidance. The stock has also incorporated developments around acquisitions such as StatLab Medical Products and integration progress on prior deals. Upcoming second-quarter earnings on July 21, 2026, with analyst expectations of $6.09 billion in revenue, represent a near-term focal point for sentiment.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots on its Trending AI Robots page. The platform features hundreds of AI trading bots that actively trade thousands of different tickers across various markets. Only those demonstrating the strongest alignment with prevailing conditions and robust statistical profiles earn placement in the trending section. Available bots span multiple trading styles, strategies, timeframes, and performance metrics, with many showing win rates in the 60-80% range and varying drawdown profiles depending on the approach. All operate with distinct sets of tickers and risk parameters. Review the full selection on the Trending AI Robots page for detailed statistics and configuration options.
Head-to-Head Comparison
Business models differ in scope: A centers on precision analytical instruments and lab workflows, while DHR employs a broader platform model across multiple verticals with greater emphasis on diagnostics and recurring revenue. Growth drivers for A include biopharma research budgets and instrument replacement cycles; DHR benefits additionally from M&A execution and end-market diversification. Recent momentum has tilted toward DHR following its earnings beat and guidance lift, whereas A has tracked sector averages more closely. Risk factors include exposure to capital expenditure cycles for both, with DHR carrying integration risks from acquisitions. Market sentiment reflects healthcare sector caution on both, though DHR’s larger scale and dividend (currently yielding approximately 0.78%) provide distinct trade-offs versus A’s more concentrated instrument focus.
Tickeron AI Verdict
Based on observable factors including earnings consistency, acquisition-related catalysts, and relative stability in recent market activity, Tickeron’s AI models currently assign a higher probabilistic weighting to DHR over A. This reflects stronger recent momentum signals and upcoming earnings visibility, though outcomes remain subject to broader market conditions and sector trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and DHR is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- DHR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while DHR’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 3 bearish.
- DHR’s TA Score: 4 bullish, 5 bearish.
Price Growth
A (@Medical Specialties) experienced а -0.14% price change this week, while DHR (@Medical Specialties) price change was +1.82% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.40%. For the same industry, the average monthly price growth was -3.39%, and the average quarterly price growth was +6.80%.
Reported Earning Dates
A is expected to report earnings on Aug 26, 2026.
DHR is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Medical Specialties (+0.40% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | DHR | A / DHR | |
| Capitalization | 39.1B | 137B | 29% |
| EBITDA | 1.96B | 7.59B | 26% |
| Gain YTD | 2.301 | -14.468 | -16% |
| P/E Ratio | 27.79 | 34.76 | 80% |
| Revenue | 7.23B | 25.1B | 29% |
| Total Cash | 1.81B | 4.35B | 42% |
| Total Debt | 3.36B | 26.6B | 13% |
A | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 45 | 79 | |
PRICE GROWTH RATING 1..100 | 26 | 52 | |
P/E GROWTH RATING 1..100 | 51 | 70 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (6) in the Biotechnology industry is in the same range as DHR (8) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DHR (100) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is somewhat better than the same rating for DHR (79) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than DHR’s over the last 12 months.
A's Price Growth Rating (26) in the Biotechnology industry is in the same range as DHR (52) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's P/E Growth Rating (51) in the Biotechnology industry is in the same range as DHR (70) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
| A | DHR | |
|---|---|---|
| RSI ODDS (%) | N/A | 4 days ago 48% |
| Stochastic ODDS (%) | 4 days ago 62% | 4 days ago 64% |
| Momentum ODDS (%) | 4 days ago 64% | 4 days ago 62% |
| MACD ODDS (%) | 4 days ago 64% | 4 days ago 65% |
| TrendWeek ODDS (%) | 4 days ago 64% | 4 days ago 55% |
| TrendMonth ODDS (%) | 4 days ago 57% | 4 days ago 54% |
| Advances ODDS (%) | 12 days ago 60% | 7 days ago 54% |
| Declines ODDS (%) | 4 days ago 64% | 4 days ago 62% |
| BollingerBands ODDS (%) | 4 days ago 68% | 4 days ago 64% |
| Aroon ODDS (%) | 4 days ago 60% | 4 days ago 65% |
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | -0.61% | ||
| TMO - DHR | 77% Closely correlated | -0.43% | ||
| A - DHR | 73% Closely correlated | -0.25% | ||
| RGEN - DHR | 68% Closely correlated | -1.80% | ||
| BIO - DHR | 64% Loosely correlated | -0.38% | ||
| BRKR - DHR | 58% Loosely correlated | -2.33% | ||
More | ||||